Search results
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks· 5 days agoThe Zacks Consensus Estimate for REGN’s first-quarter revenues is pegged at $3.2 billion, while the same for earnings is pinned at $10.20 per share. A significant chunk of Regeneron’s revenues ...
RevOpsis Welcomes Dr. Emmett Cunningham to Strategic Advisory Board
Char-Koosta News· 2 days agoRevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation in...
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
Char-Koosta News· 2 days agoCompany to present, across eight data presentations, new real-world research on the economic value...
Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com
ETF DAILY NEWS· 1 day agoEquities researchers at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued on Thursday. The brokerage set a “sell” rating ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoCognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that the company ...
Letters: Fluctuating costs of prescription drugs demand change
Chicago Tribune· 6 days agoUnjust and rapid prescription drug costs continue to put significant financial strain on Illinois...
Cognition Therapeutics hits enrollment goal in DLB study By Investing.com
Investing.com· 6 days agoCognition Therapeutics, Inc. (NASDAQ: CGTX), a biopharmaceutical company focused on...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoBEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization
Research Analysts Set Expectations for Adverum Biotechnologies, Inc.’s Q1 2024 Earnings...
ETF DAILY NEWS· 1 day agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Adverum Biotechnologies in a note ...
Is Algae Oil the New Fish Oil?
Men's Health via Yahoo News· 5 days agoAlgae oil is all the rage right now as a vegetarian replace to fish oil. Dietitians explain its health benefits, uses, and risks associated with using...
